Cambridge Investment Research Advisors, Inc. Nektar Therapeutics Transaction History

Cambridge Investment Research Advisors, Inc.

$29.6 Billion
Q1 2025

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Nektar Therapeutics stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 135,980 shares of NKTR stock, worth $89,746. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,980

Previous 126,755 7.28%

Holding current value

$89,746

Previous $118,000 22.03%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 22, 2025	BUY	$0.66 - $1.19 $6,088 - $10,977	9,225 Added 7.28%	135,980 $92,000
Q4 2024 Feb 14, 2025	SELL	$0.9 - $1.45 $4,882 - $7,866	-5,425 Reduced 4.1%	126,755 $118,000
Q3 2024 Oct 28, 2024	BUY	$1.11 - $1.48 $10,323 - $13,764	9,300 Added 7.57%	132,180 $172,000
Q2 2024 Jul 26, 2024	SELL	$0.9 - $1.83 $2,816 - $5,726	-3,129 Reduced 2.48%	122,880 $152,000
Q1 2024 Apr 24, 2024	SELL	$0.49 - $0.96 $1,911 - $3,744	-3,900 Reduced 3.0%	126,009 $118,000
Q4 2023 Feb 09, 2024	SELL	$0.42 - $0.57 $2,005 - $2,722	-4,776 Reduced 3.55%	129,909 $73,000
Q3 2023 Oct 24, 2023	SELL	$0.51 - $1.05 $1,158 - $2,385	-2,272 Reduced 1.66%	134,685 $80,000
Q2 2023 Jul 13, 2023	SELL	$0.53 - $1.03 $106 - $206	-200 Reduced 0.15%	136,957 $79,000
Q1 2023 May 11, 2023	BUY	$0.64 - $3.15 $3,152 - $15,513	4,925 Added 3.72%	137,157 $96,000
Q4 2022 Feb 08, 2023	BUY	$2.03 - $4.28 $268,430 - $565,952	132,232 New	132,232 $299,000
Q3 2021 Nov 02, 2021	SELL	$13.07 - $18.84 $134,555 - $193,957	-10,295 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$16.52 - $20.4 $413 - $509	-25 Reduced 0.24%	10,295 $176,000
Q1 2021 May 07, 2021	SELL	$16.56 - $25.46 $7,286 - $11,202	-440 Reduced 4.09%	10,320 $206,000
Q4 2020 Feb 04, 2021	SELL	$15.77 - $19.03 $17,347 - $20,933	-1,100 Reduced 9.27%	10,760 $182,000
Q3 2020 Oct 29, 2020	BUY	$16.59 - $24.79 $116 - $173	7 Added 0.06%	11,860 $196,000
Q2 2020 Jul 27, 2020	SELL	$16.86 - $23.44 $15,039 - $20,908	-892 Reduced 7.0%	11,853 $274,000
Q1 2020 May 08, 2020	SELL	$14.47 - $27.96 $8,117 - $15,685	-561 Reduced 4.22%	12,745 $227,000
Q4 2019 Feb 04, 2020	SELL	$15.87 - $23.12 $21,249 - $30,957	-1,339 Reduced 9.14%	13,306 $287,000
Q3 2019 Nov 06, 2019	BUY	$16.91 - $36.27 $2,113 - $4,533	125 Added 0.86%	14,645 $266,000
Q2 2019 Aug 15, 2019	BUY	$31.0 - $36.3 $37,789 - $44,249	1,219 Added 9.16%	14,520 $0
Q1 2019 May 08, 2019	BUY	$31.58 - $46.35 $87,002 - $127,694	2,755 Added 26.12%	13,301 $0
Q4 2018 Feb 05, 2019	SELL	$30.43 - $56.65 $40,471 - $75,344	-1,330 Reduced 11.2%	10,546 $346,000
Q3 2018 Nov 02, 2018	BUY	$46.46 - $68.49 $329,494 - $485,731	7,092 Added 148.24%	11,876 $0
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $47,082 - $106,330	1,018 Added 27.03%	4,784 $0
Q1 2018 May 09, 2018	BUY	$57.4 - $108.44 $5,740 - $10,844	100 Added 2.73%	3,766 $0
Q4 2017 Feb 22, 2018	BUY	$23.02 - $60.5 $84,391 - $221,793	3,666	3,666 $0

Others Institutions Holding NKTR

# of Institutions

155

Shares Held

130M

Call Options Held

92.7K

Put Options Held

4.9K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $124M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Nektar Therapeutics Transaction History